A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

The team tackled a critical challenge in treating multiple myeloma—a blood cancer where malignant plasma cells accumulate in bone marrow, leading to ...

The researchers also projected that newly diagnosed MM cases will increase by 70.8% by 2045 — from about 188,000 cases in 2022 to about 321,000 cases in 2045. The number of deaths due to MM is ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...

We described the first case reported in the literature of multiple myeloma in a young African woman with Systemic lupus and Sjögren Syndrome. The clinician should consider multiple myeloma in young ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing ...

are bispecific antibodies that activate T cells by targeting CD3 and that have been approved for the treatment of triple-class–exposed relapsed or refractory multiple myeloma. A total of 94 ...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to ...